FibroGen hosts KOL event on FG-3246 for metastatic castration-resistant prostate cancer

KYNTRA BIO, INC.

June 26, 2024: FibroGen and UCSF's Dr. Rahul Aggarwal presented on FG-3246 development program for mCRPC.
Presentation covers unmet need, evolving treatment landscape, and clinical development plans for FG-3246.
No financial results or new clinical data disclosed in the filing or the included exhibit.
Forward-looking statements caution that FG-3246 program involves substantial risks and uncertainties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.